Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.48 |
| ▸ | RAB9A | P51151 | 9/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16865707 | 0.93 | NPC1 (0.47) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16865704 | 0.92 | RAB9A (0.57) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL9920888 | 0.89 | NPC1 (0.43) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL19135677 | 0.86 | CYP2D6 (0.57) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16865708 | 0.86 | NPC1 (0.46) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16675917 | 0.85 | NPY5R (0.43) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16865706 | 0.85 | NPC1 (0.56) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL16865712 | 0.81 | NPC1 (0.64) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL19362745 | 0.81 | CYP2D6 (0.46) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL19362711 | 0.81 | RAB9A (0.53) | NPC1RAB9ACYP2D6SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175556-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-06-13 | — | — | US | disclosed |
| US-20170354643-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-12-14 | — | — | US | disclosed |
| US-9707211-B2 | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160287559-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-10-06 | — | — | US | disclosed |
| US-9266839-B2 | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150183745-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354643-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 3615/4885CDK2 2556/4885CCNA1 3725/4885 |
| US-20160287559-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 3615/4885CDK2 2556/4885CCNA1 3725/4885 |
| US-20190175556-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 3615/4885CDK2 2556/4885CCNA1 3725/4885 |
| US-20150183745-A1 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 3615/4885CDK2 2556/4885CCNA1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.